Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Stockton

Internal Medicine Detroit, MI Medical Doctor

NPI 1740296946 CMS profile 169518

3901 Beaubien St, Detroit, MI 48201

Open in the dashboard

General payments

$306,233

319 records reported · program years 2019–2025

Research payments

$10,597

Paid to them · 17 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$95,712 paid to institutions, not to them · program years 2019–2025

Through program year 2025, David Stockton of Detroit, MI is reported in the CMS Open Payments database as having received $306,233 across 319 general payments and $10,597 in research payments paid to them. Separately, studies naming them as principal investigator received $95,712 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $77,310 49
2024 General $38,518 34
2023 General $49,497 60
2022 General $42,435 47
2021 General $34,697 27
2021 Research $1,250 1
2020 General $15,408 16
2020 Research $4,828 8
2019 General $48,368 86
2019 Research $4,519 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Stockton
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to David Stockton were reported at $77,310. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year David Stockton Internal Medicine median Middle half National median
2019 $48,368 $159 $48–$570 $163
2020 $15,408 $119 $33–$402 $114
2021 $34,697 $135 $37–$521 $132
2022 $42,435 $141 $42–$496 $149
2023 $49,497 $149 $45–$519 $160
2024 $38,518 $154 $47–$537 $164
2025 $77,310 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $268,247 270 payments
  2. Shire North American Group Inc $16,991 29 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $15,134 14 payments
  4. Chiesi USA, Inc. $2,487 2 payments
  5. Amicus Therapeutics, Inc. $1,760 1 payment
  6. Alexion Pharmaceuticals, Inc. $1,511 2 payments
  7. BioMarin Pharmaceutical Inc. $102 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $197,041 75 payments
  2. Consulting Fee $68,852 17 payments
  3. Travel and Lodging $33,331 115 payments
  4. Food and Beverage $7,003 111 payments
  5. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. FABRAZYME Genetic Disease $59,812 49 payments
  2. CEREZYME Genetic Disease $39,431 35 payments
  3. NEXVIAZYME $35,710 40 payments
  4. CERDELGA Genetic Disease $31,349 32 payments
  5. VPRIV $30,901 41 payments
  6. LUMIZYME Rare Disease Genetics $30,140 46 payments
  7. LUMIZYME Genetic Disease $27,825 26 payments
  8. CERDELGA Rare Disease Genetics $7,554 9 payments
  9. FABRAZYME Rare Disease Genetics $7,467 10 payments
  10. CEREZYME Rare Disease Genetics $7,446 9 payments
  11. Other $18,654 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Genzyme Corporation $10,597 17 payments

Records

336 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record